{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T11:37:13Z","timestamp":1769513833739,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T00:00:00Z","timestamp":1753574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T00:00:00Z","timestamp":1753574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Over the last three decades, hepatic arterial infusion (HAI) chemotherapy combined with systemic therapy has been established as a treatment strategy for patients with unresectable liver metastases. Facilitating a HAI program outside the USA and Europe remains underutilized in regions, including Israel, and requires multidisciplinary collaboration. The purpose of this study is to describe the feasibility and early outcomes of the initiation of the first hepatic artery infusion program in Israel.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>This retrospective analysis was conducted at a tertiary medical center in Israel. It included 21 patients with unresectable colorectal liver metastases who underwent hepatic artery infusion port placement between February 2020 and March 2022. All participants underwent hepatic artery infusion port placement with most subsequently receiving chemotherapy. The study evaluated perioperative outcomes, complication rates, response rates, and conversion to resectability at 6 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Hepatic arterial infusion chemotherapy was successfully administered to 95% of patients. The overall 90-day major complication rate was 24%, with no reported mortality. At 6 months, the partial response rate was 33%, and the disease control rate was 83%. Four out of five patients (80%) with neoadjuvant intent converted from unresectable to resectable during HAI treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study demonstrates the feasibility and safety of implementing a new HAI program for carefully selected patients with colorectal liver metastases. Despite the cohort being heavily pretreated with systemic chemotherapy, promising hepatic response rates and disease control rates were observed. These findings support the potential for expanding access to HAI therapy in new geographic regions.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1245\/s10434-025-17910-9","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T22:19:50Z","timestamp":1753568390000},"page":"7200-7208","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Israel\u2019s First Port-Based Hepatic Artery Infusion Program: Early Outcomes in Colorectal Liver Metastases"],"prefix":"10.1245","volume":"32","author":[{"given":"Roy","family":"Apel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omri","family":"Sulimani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gali","family":"Perl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Abitbol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael Berger","family":"MD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shlomit","family":"Tamir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oran","family":"Zlotnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasser Abdul","family":"Halim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Tovar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baruch","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nir","family":"Wasserberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eran","family":"Sadot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,27]]},"reference":[{"issue":"1","key":"17910_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/CAAC.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333. https:\/\/doi.org\/10.3322\/CAAC.21654.","journal-title":"CA Cancer J Clin."},{"issue":"4","key":"17910_CR2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/gutjnl-2015-310912","volume":"66","author":"M Arnold","year":"2017","unstructured":"Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683\u201391. https:\/\/doi.org\/10.1136\/gutjnl-2015-310912.","journal-title":"Gut"},{"issue":"6","key":"17910_CR3","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.surg.2018.01.004","volume":"163","author":"JM Creasy","year":"2018","unstructured":"Creasy JM, Sadot E, Koerkamp BG, et al. Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure? Surgery. 2018;163(6):1238\u201344. https:\/\/doi.org\/10.1016\/j.surg.2018.01.004.","journal-title":"Surgery."},{"issue":"6","key":"17910_CR4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1200\/JCO.1984.2.6.595","volume":"2","author":"N Kemeny","year":"1984","unstructured":"Kemeny N, Daly J, Oderman P, et al. Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma. J Clin Oncol. 1984;2(6):595\u2013600. https:\/\/doi.org\/10.1200\/JCO.1984.2.6.595.","journal-title":"J Clin Oncol."},{"issue":"27","key":"17910_CR5","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJM199912303412702","volume":"341","author":"N Kemeny","year":"1999","unstructured":"Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341(27):2039\u201348. https:\/\/doi.org\/10.1056\/NEJM199912303412702.","journal-title":"N Engl J Med."},{"issue":"4","key":"17910_CR6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.7326\/0003-4819-107-4-459","volume":"107","author":"N Kemeny","year":"1987","unstructured":"Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med. 1987;107(4):459\u201365. https:\/\/doi.org\/10.7326\/0003-4819-107-4-459.","journal-title":"Ann Intern Med."},{"issue":"2","key":"17910_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/SLA.0000000000000614","volume":"261","author":"MI DAngelica","year":"2015","unstructured":"DAngelica MI, Correa-Gallego C, Paty PB, et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg. 2015;261(2):353\u201360. https:\/\/doi.org\/10.1097\/SLA.0000000000000614.","journal-title":"Ann Surg."},{"issue":"4","key":"17910_CR8","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/01.sla.0000141198.92114.f6","volume":"240","author":"R Adam","year":"2004","unstructured":"Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240(4):644\u201357. https:\/\/doi.org\/10.1097\/01.sla.0000141198.92114.f6.","journal-title":"Ann Surg."},{"issue":"8","key":"17910_CR9","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1001\/jamasurg.2019.1694","volume":"154","author":"J Datta","year":"2019","unstructured":"Datta J, Narayan RR, Kemeny NE, D\u2019Angelica MI. Role of hepatic artery infusion chemotherapy in treatment of initially unresectable colorectal liver metastases: a review. JAMA Surg. 2019;154(8):768\u201376. https:\/\/doi.org\/10.1001\/jamasurg.2019.1694.","journal-title":"JAMA Surg."},{"issue":"4","key":"17910_CR10","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/jso.24898","volume":"117","author":"LM Pak","year":"2018","unstructured":"Pak LM, Kemeny NE, Capanu M, et al. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: long term results and curative potential. J Surg Oncol. 2018;117(4):634\u201343. https:\/\/doi.org\/10.1002\/jso.24898.","journal-title":"J Surg Oncol."},{"issue":"2","key":"17910_CR11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/annonc\/mdv548","volume":"27","author":"FA L\u00e9vi","year":"2016","unstructured":"L\u00e9vi FA, Boige V, Hebbar M, et al. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol. 2016;27(2):267\u201374. https:\/\/doi.org\/10.1093\/annonc\/mdv548.","journal-title":"Ann Oncol."},{"issue":"4","key":"17910_CR12","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/SLA.0b013e3181d35983","volume":"251","author":"D Go\u00e9r\u00e9","year":"2010","unstructured":"Go\u00e9r\u00e9 D, Deshaies I, De Baere T, et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg. 2010;251(4):686\u201391. https:\/\/doi.org\/10.1097\/SLA.0b013e3181d35983.","journal-title":"Ann Surg."},{"issue":"6A","key":"17910_CR13","first-page":"743","volume":"20","author":"A Del Freo","year":"2006","unstructured":"Del Freo A, Fiorentini G, Sanguinetti F, Muttini MP, Pennucci C, Mambrini A, Cantore M. Hepatic arterial chemotherapy with oxaliplatin, folinic acid and 5-fluorouracil in pre-treated patients with liver metastases from colorectal cancer. In Vivo. 2006;20(6A):743\u20136.","journal-title":"In Vivo"},{"issue":"22","key":"17910_CR14","doi-asserted-by":"publisher","first-page":"4881","DOI":"10.1200\/JCO.2005.05.120","volume":"23","author":"M Ducreux","year":"2005","unstructured":"Ducreux M, Ychou M, Laplanche A, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the Gastrointestinal Group of the F\u00e9d\u00e9ration Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005;23(22):4881\u20137. https:\/\/doi.org\/10.1200\/JCO.2005.05.120.","journal-title":"J Clin Oncol."},{"issue":"1","key":"17910_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1245\/s10434-007-9581-7","volume":"15","author":"V Boige","year":"2008","unstructured":"Boige V, Malka D, Elias D, et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol. 2008;15(1):219\u201326. https:\/\/doi.org\/10.1245\/s10434-007-9581-7.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"17910_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3816\/ccc.2005.n.027","volume":"5","author":"RJ Kelly","year":"2005","unstructured":"Kelly RJ, Kemeny NE, Leonard GD. Current strategies using hepatic arterial infusion chemotherapy for the treatment of colorectal cancer. Clin Colorectal Cancer. 2005;5(3):166\u201374. https:\/\/doi.org\/10.3816\/ccc.2005.n.027.","journal-title":"Clin Colorectal Cancer."},{"issue":"1","key":"17910_CR17","first-page":"119","volume":"99","author":"JS Bolton","year":"1986","unstructured":"Bolton JS, Bowen JC. Biliary sclerosis associated with hepatic artery infusion of floxuridine. Surgery. 1986;99(1):119\u201322.","journal-title":"Surgery."},{"issue":"2","key":"17910_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1053\/sonc.2002.31679","volume":"29","author":"WD Ensminger","year":"2002","unstructured":"Ensminger WD. Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol. 2002;29(2):119\u201325. https:\/\/doi.org\/10.1053\/sonc.2002.31679.","journal-title":"Semin Oncol."},{"key":"17910_CR19","volume-title":"Hepat art infusion malign","author":"Berger Yael","year":"2024","unstructured":"Yael Berger, Eran Sadot. Reservoir-less ports for hepatic artery infusion. In: D\u2019Angelica Michael, Lidsky Michael, editors. Hepat art infusion malign. 1st edn. Cham: Springer; 2024.","edition":"1"},{"issue":"3","key":"17910_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.clinre.2017.11.004","volume":"42","author":"S Pernot","year":"2018","unstructured":"Pernot S, Velut G, Kourie RH, et al. 5-FU or mitomycin C hepatic arterial infusion after failure of arterial oxaliplatin in patients with colorectal cancer unresectable liver metastases. Clin Res Hepatol Gastroenterol. 2018;42(3):255\u201360. https:\/\/doi.org\/10.1016\/j.clinre.2017.11.004.","journal-title":"Clin Res Hepatol Gastroenterol."},{"issue":"6","key":"17910_CR21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/01.cad.0000131684.06390.fe","volume":"15","author":"R Dzodic","year":"2004","unstructured":"Dzodic R, Gomez-Abuin G, Rougier P, et al. Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model. Anticancer Drugs. 2004;15(6):647\u201350. https:\/\/doi.org\/10.1097\/01.cad.0000131684.06390.fe.","journal-title":"Anticancer Drugs."},{"issue":"6D","key":"17910_CR22","first-page":"5203","volume":"23","author":"I Guthoff","year":"2003","unstructured":"Guthoff I, Lotspeich E, Fester C, et al. Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. Anticancer Res. 2003;23(6D):5203\u20138.","journal-title":"Anticancer Res."},{"issue":"13","key":"17910_CR23","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1245\/s10434-020-08972-y","volume":"27","author":"JM Creasy","year":"2020","unstructured":"Creasy JM, Napier KJ, Reed SA, et al. Implementation of a hepatic artery infusion program: initial patient selection and perioperative outcomes of concurrent hepatic artery infusion and systemic chemotherapy for colorectal liver metastases. Ann Surg Oncol. 2020;27(13):5086\u201395. https:\/\/doi.org\/10.1245\/s10434-020-08972-y.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"17910_CR24","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.hpb.2019.11.013","volume":"22","author":"FE Buisman","year":"2020","unstructured":"Buisman FE, Galjart B, van der Stok EP, et al. The impact of hepatic arterial infusion pump chemotherapy on hepatic recurrences and survival in patients with resected colorectal liver metastases. HPB (Oxford). 2020;22(9):1271\u20139. https:\/\/doi.org\/10.1016\/j.hpb.2019.11.013.","journal-title":"HPB (Oxford)."},{"issue":"8","key":"17910_CR25","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1001\/archsurg.1984.01390200054013","volume":"119","author":"JM Daly","year":"1984","unstructured":"Daly JM, Kemeny N, Oderman P, Botet J. Long-term hepatic arterial infusion chemotherapy. Anatomic considerations, operative technique, and treatment morbidity. Arch Surg. 1984;119(8):936\u201341. https:\/\/doi.org\/10.1001\/archsurg.1984.01390200054013.","journal-title":"Arch Surg."},{"key":"17910_CR26","doi-asserted-by":"publisher","unstructured":"Go\u00e9r\u00e9 D, Pignon JP, Gelli M, et al. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases-a randomized phase II\/III trial-PACHA-01 (NCT02494973). https:\/\/doi.org\/10.1186\/s12885-018-4697-7","DOI":"10.1186\/s12885-018-4697-7"},{"issue":"2","key":"17910_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer."},{"issue":"3","key":"17910_CR28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","volume":"230","author":"Y Fong","year":"1999","unstructured":"Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309\u201318. https:\/\/doi.org\/10.1097\/00000658-199909000-00004.","journal-title":"Ann Surg."},{"issue":"1","key":"17910_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jamcollsurg.2005.03.019","volume":"201","author":"PJ Allen","year":"2005","unstructured":"Allen PJ, Nissan A, Picon AI, et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg. 2005;201(1):57\u201365. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2005.03.019.","journal-title":"J Am Coll Surg."},{"issue":"6","key":"17910_CR30","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1097\/SLA.0000000000005434","volume":"276","author":"JM Sharib","year":"2022","unstructured":"Sharib JM, Creasy JM, Wildman-Tobriner B, et al. Hepatic artery infusion pumps: a surgical toolkit for intraoperative decision-making and management of hepatic artery infusion-specific complications. Ann Surg. 2022;276(6):943\u201356. https:\/\/doi.org\/10.1097\/SLA.0000000000005434.","journal-title":"Ann Surg."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17910-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17910-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17910-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T14:06:17Z","timestamp":1758549977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17910-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,27]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["17910"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17910-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,27]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}